Skip to main content

Tiziana Life Sciences Ltd (TLSA)

NASDAQ: TLSA · IEX Real-Time Price · USD
1.48
-0.03 (-1.99%)
After-hours:Oct 22, 2021 5:57 PM EDT
1.51
0.01 (0.67%)
At close: Oct 22, 4:00 PM
Market Cap146.93M
Revenue (ttm)-3.60M
Net Income (ttm)-26.13M
Shares Out97.31M
EPS (ttm)-0.23
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume147,293
Open1.53
Previous Close1.50
Day's Range1.45 - 1.54
52-Week Range1.45 - 1.70
Beta-0.02
AnalystsBuy
Price Target9.00 (+496.0%)
Est. Earnings Daten/a

About TLSA

Tiziana Life Sciences plc, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology, inflammation, and infectious diseases. Its lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. The company is also developing Milciclib (TZLS-201), a small molecule inhibitor of vari...

IndustryBiotechnology
IPO DateMar 24, 2000
CEOShailubhai Kunwar
Employees11
Stock ExchangeNASDAQ
Ticker SymbolTLSA
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 2 analysts, the average rating for TLSA stock is "Buy." The 12-month stock price forecast is 9.00, which is an increase of 496.03% from the latest price.

Price Target
$9.00
(496.03% upside)
Analyst Consensus: Buy

News

Share Capital Consolidation and Commencement of trading in the New Tiziana Shares on NASDAQ

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION 2014/596/EU WHICH IS PART OF DOMESTIC UK LAW PURSUANT TO THE MARKET ABUSE (AMENDMENT) (EU EXIT) REGULATIONS (SI ...

2 days ago - GlobeNewsWire

Tiziana Life Sciences - Scheme Effective Date

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION 2014/596/EU WHICH IS PART OF DOMESTIC UK LAW PURSUANT TO THE MARKET ABUSE (AMENDMENT) (EU EXIT) REGULATIONS (SI ...

3 days ago - GlobeNewsWire

Tiziana Life Sciences plc: PDMR Dealing

LONDON and NEW YORK, Oct. 20, 2021 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (Nasdaq: TLSA / LSE: TILS) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics for o...

3 days ago - GlobeNewsWire

Tiziana Life Sciences plc: Court Sanctions the Scheme of Arrangement and approves Reduction of Capital

LONDON and NEW YORK, Oct. 19, 2021 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (Nasdaq: TLSA / LSE: TILS) ("Old Tiziana") a biotechnology company focused on innovative therapeutics for oncology, infla...

4 days ago - GlobeNewsWire

Tiziana Life Sciences Plc - Results of Court Meeting and General Meeting

LONDON, Sept. 27, 2021 (GLOBE NEWSWIRE) -- On 20 August 2021, Tiziana Life Sciences Plc (“Old Tiziana”) announced that it has formally commenced its strategic plan to change its corporate structure by e...

3 weeks ago - GlobeNewsWire

Tiziana Life Sciences plc - Interim Results for the Six Months Ended 30 June 2021

Advancing pipeline of next generation therapeutics and diagnostics for oncology and immune diseases of high unmet need Advancing pipeline of next generation therapeutics and diagnostics for oncology and...

4 weeks ago - GlobeNewsWire

Tiziana to Host Investor Call to Discuss Exclusive License Agreement to Evaluate Foralumab, a Novel, Fully Human Anti...

NEW YORK and LONDON, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (NASDAQ: TLSA, LSE: TILS) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics for o...

1 month ago - GlobeNewsWire

Tiziana Life Sciences plc Posting of Scheme Document and Notice of Meetings

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION 2014/596/EU WHICH IS PART OF DOMESTIC UK LAW PURSUANT TO THE MARKET ABUSE (AMENDMENT) (EU EXIT) REGULATIONS (SI ...

1 month ago - GlobeNewsWire

Precision BioSciences, Tiziana Life Ink Foralumab Deal For Cancer Indications

Precision BioSciences Inc (NASDAQ: DTIL) and Tiziana Life Sciences plc (NASDAQ: TLSA) have announced an exclusive license agreement for Tiziana's foralumab. The companies plan to explore the fully human...

Other symbols:DTIL
1 month ago - Benzinga

Precision BioSciences and Tiziana Life Sciences Announce Exclusive License Agreement to Evaluate Foralumab, a Novel, ...

Precision Gains Access to Tiziana's Anti-CD3 Antibody, Foralumab, to Evaluate as a Lymphodepletion Agent with its Allogeneic CAR T Portfolio Precision Gains Access to Tiziana's Anti-CD3 Antibody, Foralu...

1 month ago - GlobeNewsWire

Tiziana Life Sciences plc files scheme of arrangement to effect a corporate reorganisation and, if approved, the deli...

LONDON and NEW YORK, Aug. 20, 2021 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (Nasdaq: TLSA / LSE: TILS) ("Old Tiziana") a biotechnology company focused on innovative therapeutics for oncology, infla...

2 months ago - GlobeNewsWire

INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Tesla, Inc. and Encourages I...

Los Angeles, California--(Newsfile Corp. - August 18, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Tesl...

2 months ago - Newsfile Corp

Tiziana Announces Publication of a Peer Reviewed Article on Data from the Clinical Trial with Intranasally Administer...

NEW YORK and LONDON, Aug. 17, 2021 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (Nasdaq: TLSA / LSE: TILS) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics for o...

2 months ago - GlobeNewsWire

Tiziana Life Sciences plc Invites You to Join Us at the Q3 Virtual Investor Summit

London, United Kingdom--(Newsfile Corp. - August 16, 2021) - Tiziana Life Sciences plc (NASDAQ:TLSA) today announced that Dr. Kunwar Shailubhai, CEO & CSO will be attending the Q3 Virtual Investor Summi...

2 months ago - Newsfile Corp

Why Tiziana Life Sciences Shares Are Trading Higher Today

Tiziana Life Sciences (NASDAQ: TLSA) shares are trading higher by 16% at $2.10 as traders circulate a June 17 press release from the company titled 'Tiziana Responds to UK Call for Development of Innova...

3 months ago - Benzinga

Tiziana Life Sciences plc - ADS Ex-Dividend Date Scheduled for July 09, 2021

THIS ANNOUNCEMENT IS FOR US ADS HOLDERS ONLY

3 months ago - GlobeNewsWire

Tiziana Life Sciences plc - Distribution Dates for shares and ADRs in Accustem Sciences Limited

LONDON and NEW YORK, July 02, 2021 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics for o...

3 months ago - GlobeNewsWire

Dr Howard Weiner, Chairman of the Tiziana Scientific Advisory Board, to give an interview on Bloomberg Markets at 1.5...

NEW YORK and LONDON, June 30, 2021 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (NASDAQ: TLSA, LSE: TILS), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infe...

3 months ago - GlobeNewsWire

Tiziana Life Sciences plc (the "Company") Result of Annual General Meeting

LONDON, June 25, 2021 (GLOBE NEWSWIRE) -- At the Annual General Meeting of the Company held at 10.00 a.m. on 25 June 2021, all of the resolutions were duly passed.

3 months ago - GlobeNewsWire

Tiziana Enters a Collaboration Agreement with FHI Clinical to Conduct a Phase 2 Clinical Trial for Treating Hospitali...

NEW YORK and LONDON, June 23, 2021 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (NASDAQ: TLSA, LSE: TILS), ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics for o...

4 months ago - GlobeNewsWire

Tiziana Appoints Dr. Kevin Schutz as Vice-President of Regulatory Affairs

NEW YORK and LONDON, June 21, 2021 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (NASDAQ: TLSA, LSE: TILS), a biotechnology company focused on innovative therapeutics for oncology, neurology, inflammati...

4 months ago - GlobeNewsWire

Tiziana Responds to UK Call for Development of Innovative ‘Take Home' Treatments for COVID-19 Disease

NEW YORK and LONDON, June 17, 2021 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (NASDAQ: TLSA, LSE: TILS), a biotechnology company focused on innovative therapeutics for oncology, neurology, inflammati...

4 months ago - GlobeNewsWire

Tiziana Life Sciences plc ("Tiziana" or the “Company”) Posting of Notice of Annual General Meeting

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTION W...

4 months ago - GlobeNewsWire

US Investment bank repeats 'buy' and US$8 price target on Tiziana Life Sciences after flurry of positive news

Investment bank B Riley has restated its 'buy' advice and US$8 price target for shares in Tiziana Life Sciences PLC (LON:TILS) (NASDAQ:TLSA) after a flurry of positive news. It said safety data on key d...

4 months ago - Proactive Investors

Zacks Small-Cap Research repeats its valuation on Tiziana Life Sciences as company starts nasally administered Foralu...

Zacks Small-Cap Research has put out a note on drug developer Tiziana Life Sciences PLC (NASDAQ:TLSA) (LON:TILS), which it started covering in April this year, repeating its valuation of US$7.50 per ADR...

4 months ago - Proactive Investors